TriangleSurovatamig (NCT06526793)
Surovatamig trial for B-cell Non-Hodgkin Lymphoma (NCT06526793). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with follicular or large B-cell lymphoma that has relapsed or resisted at least two treatment lines. CD19 expression must be confirmed after progression on prior CD19-directed treatment.
The idea: surovatamig links CD3-bearing T-cells to CD19-bearing lymphoma cells, directing an immune attack. Each lymphoma group receives this antibody alone by intravenous infusion. Researchers measure partial and complete responses and safety. Previous CAR-T or transplant requires waiting periods; severe prior immune or neurologic toxicity can exclude participation.
This phase 2 study plans 270 patients. AstraZeneca sponsors sixteen recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.